{"id":177405,"date":"2011-04-07T00:00:00","date_gmt":"2011-04-06T22:00:00","guid":{"rendered":"https:\/\/hwpd.bcfi-cbip.be\/informations-recentes-avril-2011\/"},"modified":"2026-04-13T11:34:27","modified_gmt":"2026-04-13T09:34:27","slug":"informations-recentes-avril-2011","status":"publish","type":"post","link":"https:\/\/hwpd.bcfi-cbip.be\/fr\/informations-recentes-avril-2011\/","title":{"rendered":"INFORMATIONS RECENTES AVRIL 2011"},"content":{"rendered":"<div class='tekst'>\n<table style='border-bottom: medium none; border-left: medium none; border-collapse: collapse; border-top: medium none; border-right: medium none; mso-border-alt: solid windowtext .5pt; mso-yfti-tbllook: 480; mso-padding-alt: 0cm 5.4pt 0cm 5.4pt; mso-border-insideh: .5pt solid windowtext; mso-border-insidev: .5pt solid windowtext' class='MsoNormalTable' border='1' cellspacing='0' cellpadding='0'>\n<tbody>\n<tr style='mso-yfti-irow: 0; mso-yfti-firstrow: yes; mso-yfti-lastrow: yes'>\n<td style='border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding-bottom: 0cm; background-color: transparent; padding-left: 5.4pt; width: 422.3pt; padding-right: 5.4pt; border-top: windowtext 1pt solid; border-right: windowtext 1pt solid; padding-top: 0cm; mso-border-alt: solid windowtext .5pt' valign='top' width='563'>\n<p style='line-height: 200%; margin: 0cm 0cm 0pt' class='MsoNormal'><span style='font-family: Arial; letter-spacing: 1pt; mso-font-kerning: .5pt' lang='FR'><img border='0' alt='' width='10' height='10' src='\/images\/surv.gif'\/>: m\u00e9dicament \u00e0 base d\u2019un nouveau principe actif ou nouveau m\u00e9dicament biologique&#x002C; pour lequel la notification d\u2019effets ind\u00e9sirables au Centre Belge de Pharmacovigilance est encourag\u00e9e<\/span><span style='font-family: Arial; mso-ansi-language: FR-BE' lang='FR-BE'><\/p>\n<p\/><\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style='line-height: 200%; margin: 0cm 0cm 0pt' class='MsoNormal'><span style='line-height: 200%; font-family: Arial; mso-ansi-language: FR-BE' lang='FR-BE'>La num\u00e9rotation des chapitres correspond \u00e0 celle de la nouvelle \u00e9dition 2011 du R\u00e9pertoire.<\/p>\n<p\/><\/span><\/p>\n<p style='line-height: 200%; margin: 0cm 0cm 0pt' class='MsoNormal'><span style='font-family: Arial; mso-ansi-language: FR-BE' lang='FR-BE'><\/p>\n<p>\u00a0<\/p>\n<p><\/span><\/p>\n<p style='line-height: 200%; margin: 0cm 0cm 0pt' class='MsoNormal'><span style='font-family: Arial; mso-ansi-language: FR-BE' lang='FR-BE'>&#8211; La <b style='mso-bidi-font-weight: normal'>silodosine<\/b> (<b style='mso-bidi-font-weight: normal'>Silodyx<\/b>\u00ae\u00a0<\/span><span style='font-family: Arial; letter-spacing: 1pt; mso-font-kerning: .5pt' lang='FR'><img border='0' alt='' width='10' height='10' src='\/images\/surv.gif'\/><\/span><span style='font-family: Arial; mso-ansi-language: FR-BE' lang='FR-BE'>; chapitre 7.2.1.) est un nouvel \u03b1<sub>1<\/sub>-bloquant propos\u00e9 dans le traitement symptomatique de l\u2019hypertrophie b\u00e9nigne de la prostate. La silodosine n\u2019est pas moins efficace que la tamsulosine&#x002C; un autre \u03b1<sub>1<\/sub>-bloquant (preuve de non-inf\u00e9riorit\u00e9). Les effets ind\u00e9sirables sont ceux des \u03b1<sub>1<\/sub>-bloquants en g\u00e9n\u00e9ral&#x002C; entre autres hypotension&#x002C; vertiges&#x002C; syndrome de l\u2019iris flasque [voir Folia de mars 2010]. Dans une \u00e9tude comparative avec la tamsulosine&#x002C; la silodosine a entra\u00een\u00e9 plus fr\u00e9quemment des troubles de l\u2019\u00e9jaculation (\u00e9jaculation r\u00e9trograde&#x002C; an\u00e9jaculation). La silodosine est un substrat du CYP3A4 et de la glycoprot\u00e9ine P&#x002C; ce qui expose \u00e0 un risque d\u2019interactions [voir tableau dans l\u2019Introduction du R\u00e9pertoire]. Il convient \u00e9galement de tenir compte de son co\u00fbt plus \u00e9lev\u00e9 par rapport aux m\u00e9dicaments plus anciens pour le traitement symptomatique de l\u2019hypertrophie b\u00e9nigne de la prostate. [Voir aussi la Fiche de transparence \u00ab\u00a0Prise en charge de l\u2019hypertrophie b\u00e9nigne de la prostate\u00a0\u00bb].<\/p>\n<p\/><\/span><\/p>\n<p style='line-height: 200%; margin: 0cm 0cm 0pt' class='MsoNormal'><span style='font-family: Arial; mso-ansi-language: FR-BE' lang='FR-BE'>&#8211; L\u2019<b style='mso-bidi-font-weight: normal'>indacat\u00e9ro<\/b>l (<b style='mso-bidi-font-weight: normal'>Onbrez Breezhaler<\/b>\u00ae\u00a0<\/span><span style='font-family: Arial; letter-spacing: 1pt; mso-font-kerning: .5pt' lang='FR'><img border='0' alt='' width='10' height='10' src='\/images\/surv.gif'\/><\/span><span style='font-family: Arial; mso-ansi-language: FR-BE' lang='FR-BE'>; chapitre 4.1.1.2.) est un nouveau \u03b2<sub>2<\/sub>-mim\u00e9tique \u00e0 longue dur\u00e9e d\u2019action propos\u00e9 dans le traitement d\u2019entretien de la<span style='mso-spacerun: yes'>\u00a0 <\/span>bronchopneumopathie chronique obstructive (BPCO). L\u2019effet bronchodilatateur appara\u00eet dans un d\u00e9lai de 5 minutes et se maintient pendant 24 heures. La posologie recommand\u00e9e est de 150 \u00e0 300 \u00b5g en une seule inhalation par jour&#x002C; \u00e0 l\u2019aide de l\u2019inhalateur fourni. Les effets ind\u00e9sirables de l\u2019indacat\u00e9rol sont comparables \u00e0 ceux des autres \u03b2<sub>2<\/sub>-mim\u00e9tiques et consistent surtout en des infections des voies respiratoires&#x002C; de la toux&#x002C; des c\u00e9phal\u00e9es et des tremblements. Des \u00e9tudes randomis\u00e9es sur une p\u00e9riode de maximum un an chez des patients atteints de BPCO ont montr\u00e9 que l\u2019indacat\u00e9rol n\u2019\u00e9tait pas moins efficace que le formot\u00e9rol (un autre \u03b2<sub>2<\/sub>-mim\u00e9tique \u00e0 longue dur\u00e9e) et le tiotropium (un anticholinergique \u00e0 longue dur\u00e9e d\u2019action) en ce qui concerne l\u2019am\u00e9lioration des sympt\u00f4mes (preuve de non-inf\u00e9riorit\u00e9). Des \u00e9tudes comparatives avec d\u2019autres bronchodilatateurs \u00e0 longue dur\u00e9e d\u2019action font cependant d\u00e9faut en ce qui concerne les effets \u00e0 long terme. [En ce qui concerne le traitement d\u2019entretien de la BPCO&#x002C; voir Folia de janvier 2007 et d\u2019avril 2007].<\/p>\n<p\/><\/span><\/p>\n<p>\u00a0<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>: m\u00e9dicament \u00e0 base d\u2019un nouveau principe actif ou nouveau  [&#8230;]<\/p>\n","protected":false},"author":9,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[12,52],"tags":[20213,20224],"class_list":["post-177405","post","type-post","status-publish","format-standard","hentry","category-actualites","category-2011-fr","tag-import_tags","tag-import_tags-nl"],"_links":{"self":[{"href":"https:\/\/hwpd.bcfi-cbip.be\/fr\/wp-json\/wp\/v2\/posts\/177405","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/hwpd.bcfi-cbip.be\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/hwpd.bcfi-cbip.be\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/hwpd.bcfi-cbip.be\/fr\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/hwpd.bcfi-cbip.be\/fr\/wp-json\/wp\/v2\/comments?post=177405"}],"version-history":[{"count":1,"href":"https:\/\/hwpd.bcfi-cbip.be\/fr\/wp-json\/wp\/v2\/posts\/177405\/revisions"}],"predecessor-version":[{"id":179979,"href":"https:\/\/hwpd.bcfi-cbip.be\/fr\/wp-json\/wp\/v2\/posts\/177405\/revisions\/179979"}],"wp:attachment":[{"href":"https:\/\/hwpd.bcfi-cbip.be\/fr\/wp-json\/wp\/v2\/media?parent=177405"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/hwpd.bcfi-cbip.be\/fr\/wp-json\/wp\/v2\/categories?post=177405"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/hwpd.bcfi-cbip.be\/fr\/wp-json\/wp\/v2\/tags?post=177405"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}